WorldHeart cuts workforce by 42% as it ditches Levacor
This article was originally published in Clinica
Executive Summary
WorldHeart has discontinued development of its lead product, the Levacor heart pump, and is laying off 21 out of 50 employees. The firm said it does not believe the product can be competitively commercialised because of delays in its bridge-to-transplant trial, which originally got the go-ahead from the US FDA in January 2010 (www.clinica.co.uk, 11 January 2010).